{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-391328","form_type":"8-K","ticker":"BLSM","cik":"0001839970","company_name":"BlossomHill Therapeutics, Inc.","filed_at":"2026-09-15T11:30:06+00:00","discovered_at":"2026-09-15T11:35:00.552307+00:00","generated_at":"2026-09-15T11:35:08.835051+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BlossomHill reports 45% ORR for BH-30643 in EGFR C797S-positive NSCLC from SOLARA trial","bullets":["ORR 45% (18/40) and DCR 88% (35/40) in EGFR C797S-positive NSCLC patients with prior EGFR inhibitor resistance, ± T790M.","63% (25/40) remained on treatment at median follow-up 6.9 months; 98% had prior osimertinib, 35% concurrent T790M.","Safety (n=174, 40/50/60 mg BID): treatment-related dose reductions 9%, discontinuations 3%; common AE bilirubin elevation.","Plans global Phase 2 targeting EGFR C797S-positive NSCLC in Q1 2027; FDA Fast Track designation previously granted.","Activity seen across pretreated population: median 2 prior lines; 53% prior chemo/ADC; 53% history of brain metastases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-391328","json":"https://secwatch.observer/filing/0001193125-26-391328.json","markdown":"https://secwatch.observer/filing/0001193125-26-391328.md","text":"https://secwatch.observer/filing/0001193125-26-391328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526391328/0001193125-26-391328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526391328/d168153d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T11:35:08.835051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}